Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.

@article{Armstrong2005HematologicSA,
  title={Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.},
  author={Deborah King Armstrong and David S. Spriggs and Jeremey Levin and Ruth Poulin and Stephen J. Lane},
  journal={The oncologist},
  year={2005},
  volume={10 9},
  pages={
          686-94
        }
}
The purpose was to conduct an integrated analysis of the cumulative hematologic toxicity of topotecan in patients with relapsed ovarian cancer and small cell lung cancer (SCLC). Data were pooled from eight phase II and phase III clinical studies performed in patients with relapsed stage III/IV ovarian cancer or extensive SCLC treated with topotecan at a dose of 1.5 mg/m(2) per day on days 1-5 of a 21-day course. Quantitative hematologic toxicities were assessed using the National Cancer… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Similar Papers

Loading similar papers…